Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics

Gerckens, Michael ; Schorpp, Kenji ; Pelizza, Francesco ; Wögrath, Melanie ; Reichau, Kora ; Ma, Huilong ; Dworsky, Armando Marco ; Sengupta, Arunima ; Stoleriu, Mircea Gabriel and Heinzelmann, Katharina , et al. (2021) In Science Advances 7(52). p.1-19
Abstract

Fibrogenic processes instigate fatal chronic diseases leading to organ failure and death. Underlying biological processes involve induced massive deposition of extracellular matrix (ECM) by aberrant fibroblasts. We subjected diseased primary human lung fibroblasts to an advanced three-dimensional phenotypic high-content assay and screened a repurposing drug library of small molecules for inhibiting ECM deposition. Fibrotic Pattern Detection by Artificial Intelligence identified tranilast as an effective inhibitor. Structure-activity relationship studies confirmed N-(2-butoxyphenyl)-3-(phenyl)acrylamides (N23Ps) as a novel and highly potent compound class. N23Ps suppressed myofibroblast transdifferentiation, ECM deposition, cellular... (More)

Fibrogenic processes instigate fatal chronic diseases leading to organ failure and death. Underlying biological processes involve induced massive deposition of extracellular matrix (ECM) by aberrant fibroblasts. We subjected diseased primary human lung fibroblasts to an advanced three-dimensional phenotypic high-content assay and screened a repurposing drug library of small molecules for inhibiting ECM deposition. Fibrotic Pattern Detection by Artificial Intelligence identified tranilast as an effective inhibitor. Structure-activity relationship studies confirmed N-(2-butoxyphenyl)-3-(phenyl)acrylamides (N23Ps) as a novel and highly potent compound class. N23Ps suppressed myofibroblast transdifferentiation, ECM deposition, cellular contractility, and altered cell shapes, thus advocating a unique mode of action. Mechanistically, transcriptomics identified SMURF2 as a potential therapeutic target network. Antifibrotic activity of N23Ps was verified by proteomics in a human ex vivo tissue fibrosis disease model, suppressing profibrotic markers SERPINE1 and CXCL8. Conclusively, N23Ps are a novel class of highly potent compounds inhibiting organ fibrosis in patients.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Science Advances
volume
7
issue
52
article number
eabb3673
pages
1 - 19
publisher
American Association for the Advancement of Science (AAAS)
external identifiers
  • pmid:34936468
  • scopus:85122002670
ISSN
2375-2548
DOI
10.1126/sciadv.abb3673
language
English
LU publication?
yes
additional info
Publisher Copyright: Copyright © 2021 The Authors, some rights reserved.
id
064e3270-be0c-48d1-8e8e-b8398ac991ef
date added to LUP
2022-01-17 14:49:06
date last changed
2024-05-18 22:24:45
@article{064e3270-be0c-48d1-8e8e-b8398ac991ef,
  abstract     = {{<p>Fibrogenic processes instigate fatal chronic diseases leading to organ failure and death. Underlying biological processes involve induced massive deposition of extracellular matrix (ECM) by aberrant fibroblasts. We subjected diseased primary human lung fibroblasts to an advanced three-dimensional phenotypic high-content assay and screened a repurposing drug library of small molecules for inhibiting ECM deposition. Fibrotic Pattern Detection by Artificial Intelligence identified tranilast as an effective inhibitor. Structure-activity relationship studies confirmed N-(2-butoxyphenyl)-3-(phenyl)acrylamides (N23Ps) as a novel and highly potent compound class. N23Ps suppressed myofibroblast transdifferentiation, ECM deposition, cellular contractility, and altered cell shapes, thus advocating a unique mode of action. Mechanistically, transcriptomics identified SMURF2 as a potential therapeutic target network. Antifibrotic activity of N23Ps was verified by proteomics in a human ex vivo tissue fibrosis disease model, suppressing profibrotic markers SERPINE1 and CXCL8. Conclusively, N23Ps are a novel class of highly potent compounds inhibiting organ fibrosis in patients. </p>}},
  author       = {{Gerckens, Michael and Schorpp, Kenji and Pelizza, Francesco and Wögrath, Melanie and Reichau, Kora and Ma, Huilong and Dworsky, Armando Marco and Sengupta, Arunima and Stoleriu, Mircea Gabriel and Heinzelmann, Katharina and Merl-Pham, Juliane and Irmler, Martin and Alsafadi, Hani N. and Trenkenschuh, Eduard and Sarnova, Lenka and Jirouskova, Marketa and Frieß, Wolfgang and Hauck, Stefanie M. and Beckers, Johannes and Kneidinger, Nikolaus and Behr, Jürgen and Hilgendorff, Anne and Hadian, Kamyar and Lindner, Michael and Königshoff, Melanie and Eickelberg, Oliver and Gregor, Martin and Plettenburg, Oliver and Yildirim, Ali Önder and Burgstaller, Gerald}},
  issn         = {{2375-2548}},
  language     = {{eng}},
  number       = {{52}},
  pages        = {{1--19}},
  publisher    = {{American Association for the Advancement of Science (AAAS)}},
  series       = {{Science Advances}},
  title        = {{Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics}},
  url          = {{http://dx.doi.org/10.1126/sciadv.abb3673}},
  doi          = {{10.1126/sciadv.abb3673}},
  volume       = {{7}},
  year         = {{2021}},
}